PPL 103
Alternative Names: Opioid derivatives - Phoenix PharmaLabs; PPL-103Latest Information Update: 28 Dec 2024
At a glance
- Originator Phoenix PharmaLabs
- Developer Aoxing Pharmaceutical Company; Phoenix PharmaLabs
- Class Opioid analgesics
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain; Substance-related disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Pain in China
- 28 Dec 2024 No recent reports of development identified for preclinical development in Pain in USA
- 28 Dec 2024 No recent reports of development identified for preclinical development in Substance-related disorders in China